Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
29 July 2022 |
Main ID: |
NCT02425891 |
Date of registration:
|
21/04/2015 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)
|
Scientific title:
|
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer |
Date of first enrolment:
|
June 23, 2015 |
Target sample size:
|
902 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/show/NCT02425891 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
|
Phase:
|
Phase 3
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Austria
|
Belgium
|
Bosnia and Herzegovina
|
Brazil
|
Canada
|
Chile
|
Colombia
|
Costa Rica
|
Czech Republic
|
Czechia
|
Denmark
|
Estonia
|
Finland
|
France
|
Germany
|
Greece
|
Guatemala
|
Hong Kong
|
Hungary
|
Italy
|
Japan
|
Korea, Republic of
|
Latvia
|
Mexico
|
Norway
|
Panama
|
Poland
|
Portugal
|
Romania
|
Russian Federation
|
Serbia
|
Singapore
|
Slovenia
|
Spain
|
Sweden
|
Switzerland
|
Taiwan
|
Thailand
|
Turkey
|
Ukraine
|
United Kingdom
|
United States
| | | | |
Contacts
|
Name:
|
Clinical Trials |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Hoffmann-La Roche |
| | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
|